Eotaxin _ CCL11
- Known as:
- Eotaxin _ CCL11
- Catalog number:
- GTX12459
- Product Quantity:
- 25 µg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- Eotaxin _ CCL11
Related genes to: Eotaxin _ CCL11
- Gene:
- CCL11 NIH gene
- Name:
- C-C motif chemokine ligand 11
- Previous symbol:
- SCYA11
- Synonyms:
- eotaxin, MGC22554
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 1996-04-24
- Date modifiied:
- 2016-10-05
Related products to: Eotaxin _ CCL11
Related articles to: Eotaxin _ CCL11
- : Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous type 2 inflammatory disease characterized by frequent postoperative recurrence despite endoscopic sinus surgery (ESS). Reliable biomarkers capable of predicting recurrence remain insufficiently validated. This study evaluates the prognostic utility of circulating biomarkers for recurrence prediction in CRSwNP, in addition to the predictive performance of the blood eosinophilia. : A prospective cohort of 69 patients with CRSwNP undergoing primary ESS was followed for up to 3 years. Periostin, eotaxin-3, procalcitonin and IL-33 were taken from blood before surgery and analyzed by ELISA technique. Clinical outcomes were assessed using SNOT-22 and Perioperative Sinus Endoscopy (POSE) scores. Statistical analyses included Spearman's correlation, the Mann-Whitney U test, the Kruskal-Wallis test, Cox proportional hazards regression, multivariable binary logistic regression, ROC analysis, and longitudinal MANCOVA. : Blood eosinophilia remained the strongest clinical predictor of recurrence (OR = 4.55, = 0.001). Serum periostin, eotaxin and procalcitonin significantly correlated with postoperative disease severity and recurrence, particularly with POSE scores at 1 and 3 years ( < 0.05). Patients with recurrence demonstrated significantly higher serum levels of these biomarkers compared with controlled patients (all < 0.001). Multivariate Cox regression identified periostin (HR = 1.033, = 0.010), eotaxin (HR = 1.554, < 0.001) and procalcitonin (HR = 1.183, < 0.001) as significant predictors of recurrence. Procalcitonin demonstrated the highest predictive performance in ROC analysis (AUC = 0.805). Longitudinal MANCOVA confirmed significant associations between periostin, eotaxin, procalcitonin, and persistent postoperative inflammatory burden over 3 years. : Circulating periostin, eotaxin and procalcitonin are promising predictors of CRSwNP recurrence and appear to contribute to prognostic accuracy. Integration of serum biomarker profiling into clinical practice may improve personalized postoperative management and risk stratification in CRSwNP. - Source: PubMed
Publication date: 2026/07/27
Florean Maria-DeliaMare CodruțaGâta AndaTrombitaș Veronica ElenaBudișan LiviuțaZanoaga OanaBerindan-Neagoe IoanaStelea Carmen GabrielaRoman AlexandraAlbu Silviu - Age-related skeletal muscle atrophy (sarcopenia) poses a major public health challenge, emphasizing the need for safe and effective interventions. Our previous studies demonstrated that C-C chemokine receptor type 5 (CCR5) is a key therapeutic target for skeletal muscle atrophy, as its activation by C-C motif chemokine ligand 11 (CCL11) promotes the dissociation and degradation of the structural protein α-actin, ultimately contributing to muscle loss. To identify potential CCR5 inhibitors, a database of 7860 natural alkaloids was constructed for pharmacophore-based virtual screening using the CCR5-Maraviroc crystal structure. Screening yielded 789 candidates, and subsequent batch molecular docking analysis identified Isoliensinine (ISO), a lotus seed alkaloid, as a potential CCR5 inhibitor with low binding energy (-10 kcal/mol) and stable hydrogen bonding interactions with Glu283 and Tyr251. Molecular dynamics simulations further confirmed the structural stability of the ISO-CCR5 complex. Molecular dynamics simulations further confirmed the structural stability of the ISO-CCR5 complex. In vitro, ISO dose-dependently inhibited CCL11-induced CCR5 activity (IC = 1.314 μM) with low cytotoxicity in C2C12 myotubes, and markedly alleviated CCL11-induced myotube atrophy by suppressing CCR5 activation and the upregulation of the muscle atrophy-related markers MAFbx and MuRF1. These findings provide preliminary evidence for ISO as a potential CCR5-targeting candidate for further investigation in sarcopenia. - Source: PubMed
Publication date: 2026/08/14
Qu TaiqiChen YujuanZhang YijiaWang YuanLi YixuanSun Yanan - Children with autism spectrum disorder (ASD) exhibit gut mucosal immune alterations, but the co-regulatory architecture linking stool immune proteins and cytokines within the same cohort remains unstudied. In 115 children (74 ASD, 41 controls; age 5-18 years), seven stool immune proteins (IgA subclasses, α-antitrypsin and calprotectin subunits) were quantified by UHPLC-MS/MS and ten by Luminex-chemokines eotaxin/CCL11 and IL-8/CXCL8 plus eight cytokines-each normalised to total protein. Age-adjusted partial Spearman correlations were computed for all 70 protein-cytokine pairs per stratum, using Benjamini-Hochberg correction, bootstrap confidence intervals and Fisher r-to-z tests. No pair survived FDR correction in any stratum. IgA1 and IL-1β/TP correlated positively across all strata (full cohort ρ = 0.409, 95% CI 0.131-0.634, = 62; controls 0.583; ASD 0.210), with no significant between-group difference (Fisher z = 1.70, = 0.090). Multiple imputation attenuated this to ρ = 0.265 (95% CI 0.055-0.452). An inverse trend between IL-1β/TP and CARS score (ρ = -0.336, = 41) did not survive correction (-FDR = 0.576). This power-limited, hypothesis-generating study identifies an exploratory IgA1-IL-1β mucosal axis present across groups, with no confirmed between-group difference. Adequately powered multi-centre studies are required. - Source: PubMed
Publication date: 2026/08/07
Osredkar JoškoGodnov UrošVrhovšek Maja JekovecOsredkar DamjanAvguštin GorazdFabjan TejaKumer Kristina - Ischemia/Reperfusion (I/R) and the increasing age of patients are coexisting challenges in today's cardiovascular medicine. Vascular I/R leads to endothelial dysfunction and is partially driven by inflammation. With increasing age, a profile of biomolecules known as the senescence-associated secretory phenotype (SASP) also increases. The SASP correlates with decreased resilience and intrinsic capacity to withstand various stressors and contains pro-inflammatory cytokines, likely fueling I/R injury. Senomorphics block SASP secretion. We investigated the effect of ruxolitinib on endothelial function after vascular I/R injury in middle-aged and old mice. - Source: PubMed
Publication date: 2026/08/22
Saemann LarsSoyer Hatice SedaPohl SabineHagewiesche SaskiaSarow LeahWambrauw SaraKuru-Schors MerveSimm Andreas - (PV) is a severe autoimmune blistering disease characterized by pathogenic autoantibodies primarily targeting desmoglein-3. B-cell depletion by rituximab (anti-CD20) is an effective first-line treatment for PV; however, relapses are frequently observed. Evidence suggests that PV is associated with immune dysregulation beyond the B-cell compartment. So far, existing studies have largely focused on selected immune components or populations, or specific clinical states such as active disease, remission, or immediate post-rituximab, leaving it unclear how prior rituximab treatment shapes the overall circulating immune landscape during active PV, including relapse. In this study, we performed high-dimensional immune profiling to characterize circulating immune-cell composition and cytokine/chemokine signatures using a 40-colour spectral flow cytometry panel and a 46-plex Luminex assay, respectively. We compared active PV patients with healthy controls and performed a subgroup analysis of rituximab-naive versus rituximab-experienced relapsed PV patients. High-dimensional immune profiling showed that active PV is associated with a redistribution of circulating immune cells, with increased monocytes and decreased lymphocytes and plasmacytoid dendritic cells, together with reduced frequencies of double-negative (CD4CD8) T cells and T follicular helper cells compared with healthy controls. When comparing rituximab-naive with rituximab-experienced PV patients, in rituximab-experienced patients, the cellular composition changes were confined to the B-cell compartment, showing a shift toward a naive-dominant B-cell subset distribution. In parallel, PV was characterized by elevated serum concentrations of CD40L, CCL11/eotaxin, G-CSF, IL-1RA, IL-7, CCL20/MIP-3α, PD-L1/B7-H1/CD274, PDGF-AB/BB, and CCL5/RANTES, while no differences were identified between rituximab-naive patients and rituximab-experienced relapsed PV patients. Correlation analysis revealed that prednisone dosage may increase the frequency of mature B cells, and levels of CCL11/eotaxin, and IL-7, while decreasing the frequency of plasmacytoid dendritic cells and T follicular helper cells. Together, these findings reveal a systemic immune signature of active PV involving changes in circulating monocyte, T-cell, and soluble immune compartments, whereas prior rituximab exposure in relapsed patients is associated with sustained remodelling confined to B-cell subset composition, without long-term restructuring of non-B-cell immune lineages. - Source: PubMed
Publication date: 2026/08/03
Strandmoe Anne-LiseBonasia Carlo GInrueangsri NanthichaAbdulahad Wayel HStrating Inge MMennega Kevin PBijma TheoDiercks Gilles F HBremer JeroenLaman Jon DHorváth BarbaraHeeringa Peter